Market Overview

UPDATE: Morgan Stanley Reiterates On Idenix Pharmaceuticals Due To Likely Merck Acquisition


In a report published Tuesday, Morgan Stanley analyst David Friedman reiterated an Equal-Weight rating on Idenix Pharmaceuticals (NASDAQ: IDIX), and raised the price target from $5.00 to $24.50.

In the report, Morgan Stanley noted, “We are increasing our price target to $24.50 in light of Merck's announced bid for Idenix at $24.50/share. We do not expect other bidders for this company or any data to cause the deal to not happen...We are Equal-weight IDIX and have a $24.50 price target, which is driven by Merck's announced acquisition price for Idenix. We do not expect other bidders for Idenix.”

Idenix Pharmaceuticals closed on Monday at $23.80.

Latest Ratings for IDIX

Jun 2014UBSDowngradesBuyNeutral
Jun 2014BairdUpgradesUnderperformNeutral
Jan 2014JMP SecuritiesDowngradesMarket PerformMarket Underperform

View More Analyst Ratings for IDIX
View the Latest Analyst Ratings


Related Articles (IDIX)

View Comments and Join the Discussion!

Posted-In: David Friedman Morgan StanleyAnalyst Color Price Target Analyst Ratings

Latest Ratings

DEBMO CapitalMaintains400.0
PRITruist SecuritiesMaintains165.0
SHAKJP MorganMaintains70.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at